UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 10-Q
(Mark One)
[ X ] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 1998
-------------------------------------------------
OR
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the transition period from ______________________ to ______________________
Commission file number 0-26206
Norland Medical Systems, Inc.
- --------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 06-1387931
- ------------------------------- -------------------
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
106 Corporate Park Drive, Suite 106
White Plains, New York 10604
- --------------------------------------------------------------------------------
(Address of principal executive offices)
(Zip Code)
(914) 694-2285
- --------------------------------------------------------------------------------
(Registrant's telephone number, including area code)
- --------------------------------------------------------------------------------
(Former name, former address and former fiscal year,
if changed since last report)
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.
Yes |X| No |_|
As of May 11, 1998, 7,164,031 shares of the registrant's Common Stock,
$0.0005 par value, were outstanding.
-1-
<PAGE>
NORLAND MEDICAL SYSTEMS, INC.
TABLE OF CONTENTS FOR FORM 10-Q
Page
----
Title Page.....................................................................1
Document Table of Contents.....................................................2
Introduction...................................................................3
PART I FINANCIAL INFORMATION.................................................4
Item 1. Condensed Consolidated Financial Statements...........................4
Condensed Consolidated Balance Sheets.................................4
Condensed Consolidated Statements of Operations.......................5
Condensed Consolidated Statements of Cash Flows.......................6
Notes to Condensed Consolidated Financial Statements..................7
Item 2. Management's Discussion and Analysis of Financial Condition
and Results of Operations............................................12
PART II OTHER INFORMATION....................................................16
Item 1. Legal Proceedings....................................................16
Item 2. Changes in Securities................................................17
Item 3. Defaults Upon Senior Securities......................................17
Item 4. Submission of Matters to a Vote of Security Holders..................18
Item 5. Other Information....................................................18
Item 6. Exhibits and Reports on Form 8-K.....................................18
Signatures....................................................................19
Exhibit Index.................................................................20
-2-
<PAGE>
Norland Medical Systems, Inc.
I N T R O D U C T I O N
The statements included in this Report regarding future financial
performance and results and the other statements that are not historical facts
are forward-looking statements. The words "believes," "intends," "expects,"
"anticipates," "projects," "estimates," "predicts," and similar expressions are
also intended to identify forward-looking statements. These forward-looking
statements are based on current expectations and are subject to risks and
uncertainties. In connection with the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995, the Company cautions the reader that
actual results or events could differ materially from those set forth or implied
by the forward-looking statements and related assumptions due to certain
important factors, including, without limitation, the following: (i) the
continued development of new products and product enhancements that can be
marketed by the Company; (ii) the importance to the Company's sales growth that
the efficacy of new therapies for the treatment of osteoporosis and other bone
disorders be demonstrated and that regulatory approval of such therapies be
granted, particularly in the United States; (iii) the acceptance and adoption by
primary care providers of new osteoporosis therapies and the Company's ability
to expand sales of its products to these physicians; (iv) the Company may be
adversely affected by changes in the reimbursement policies of governmental
programs (e.g., Medicare and Medicaid) and private third party payors, including
private insurance plans and managed care plans; (v) the high level of
competition in the bone densitometry market; (vi) changes in bone densitometry
technology; (vii) the Company's ability to continue to maintain and expand
acceptable relationships with third party dealers and distributors; (viii) the
Company's ability to provide attractive financing options to its customers and
to provide customers with fast and efficient service for the Company's products;
(ix) changes that may result from health care reform in the United States may
adversely affect the Company; and (x) other risks described elsewhere in this
Report and in other documents filed by the Company with the Securities and
Exchange Commission. The Company is also subject to general business risks,
including adverse state, federal, or foreign legislation and regulation, adverse
publicity or news coverage, changes in general economic factors, and the
Company's ability to retain and attract key employees. The Company's actual
results could differ materially from those anticipated in these forward-looking
statements as a result of certain factors.
On March 16, 1998, the Company announced that it would restate its revenues
downward for the fourth quarter of 1996 and for the first, second, and third
quarters of 1997. Financial statements and related disclosures contained in this
Report with respect to the quarter ended March 31, 1997, reflect the restated
financial statements for such quarter (see Note 6 to the Condensed Consolidated
Financial Statements in Item 1 of this Report). The balance sheet and related
disclosures with respect to the year ended December 31, 1997 reflect the
restated consolidated financial statements for the first three quarters of the
year.
-3-
<PAGE>
Norland Medical Systems, Inc.
PART I FINANCIAL INFORMATION
Item 1. Condensed Consolidated Financial Statements
Norland Medical Systems, Inc.
Condensed Consolidated Balance Sheets
(Unaudited)
<TABLE>
<CAPTION>
March 31, 1998 December 31, 1997
-------------- -----------------
<S> <C> <C>
ASSETS
Current assets:
Cash and cash equivalents $ 1,449,188 $ 3,082,202
Accounts receivable - trade, less allowance for
doubtful accounts of $2,200,000 at March 31, 1998
and December 31, 1997 4,227,678 6,165,467
Income taxes receivable 853,508 1,774,314
Inventories, net 5,878,615 5,163,682
Officer's loan receivable 87,688 86,504
Prepaid expenses and other current assets 210,079 207,221
Deferred income taxes 2,681,210 2,559,758
------------ ------------
Total current assets 15,387,966 19,039,148
------------ ------------
Demonstration systems inventory, net 59,794 67,594
Investment in Vitel, Inc. 260,000 260,000
Property and equipment, net 853,448 807,572
Deferred income taxes 1,587,083 458,535
Goodwill, net 8,596,912 8,745,676
------------ ------------
Total assets $ 26,745,203 $ 29,378,525
============ ============
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Current portion of note payable $ 1,112,094 $ 1,122,788
Accounts payable - related parties 544,370 584,779
Accounts payable - trade 1,412,854 2,021,904
Accrued expenses 2,455,388 2,208,313
Accrued warranty expenses 890,000 890,000
Customer deposits 125,000 500,000
------------ ------------
Total current liabilities 6,539,706 7,327,784
------------ ------------
Note payable, net of discount 14,484,093 14,439,756
Stockholders' equity:
Common stock, par value of $0.0005 per share,
20,000,000 shares authorized, 7,164,031 and
7,162,531 shares issued at March 31, 1998 and
December 31, 1997, respectively 3,581 3,580
Additional paid-in capital 22,245,686 22,245,686
Accumulated deficit (16,527,863) (14,638,281)
------------ ------------
Total stockholders' equity 5,721,404 7,610,985
------------ ------------
Total liabilities and stockholders' equity $ 26,745,203 $ 29,378,525
============ ============
</TABLE>
See accompanying notes to condensed consolidated financial statements
-4-
<PAGE>
Norland Medical Systems, Inc.
Condensed Consolidated Statements of Operations
(Unaudited)
For the Three Months Ended
------------------------------
March 31, 1998 March 31, 1997
-------------- --------------
Revenue $ 2,062,707 $4,337,203
Cost of revenue 1,805,914 2,482,874
----------- ----------
Gross profit 256,793 1,854,329
Sales and marketing expense 1,664,575 1,102,140
General and administrative expense 1,037,809 601,180
Research and development expense 419,842 113,287
----------- ----------
Operating (loss) income (2,865,433) 37,722
Interest expense (318,018) --
Interest income 43,869 136,894
----------- ----------
(Loss) income before income taxes (3,139,582) 174,616
(Benefit) provision for income taxes (1,250,000) 71,000
----------- ----------
Net (loss) income $(1,889,582) $ 103,616
=========== ==========
Weighted average number of common and
common equivalent shares:
Basic 7,163,314 7,115,831
Diluted 7,163,314 7,166,878
(Loss) earnings per share:
Basic $ (0.26) $ 0.01
Diluted $ (0.26) $ 0.01
See accompanying notes to condensed consolidated financial statements.
-5-
<PAGE>
Norland Medical Systems, Inc.
Condensed Consolidated Statements of Cash Flows
(Unaudited)
<TABLE>
<CAPTION>
For the Three Months Ended
------------------------------
March 31, 1998 March 31, 1997
-------------- --------------
<S> <C> <C>
Cash flows from operating activities:
Net (loss) income $(1,889,582) $ 103,616
Adjustments to reconcile net (loss) income to net cash
used in operating activities:
Amortization expense 190,206 96,544
Depreciation expense 67,854 28,182
Inventory obsolescence expense 325,000 --
Deferred income taxes (1,250,000) --
Changes in assets and liabilities:
Accounts receivable 1,937,789 876,156
Inventories (1,039,932) (1,602,478)
Prepaid expenses and other current assets (2,858) (189,450)
Accounts payable (649,459) (493,684)
Accrued expenses 247,075 (71,754)
Income taxes receivable 920,806 (18,588)
Customer deposits (375,000) (7,350)
----------- -----------
Total adjustments 371,481 (1,382,422)
----------- -----------
Net cash used in
operating activities (1,518,101) (1,278,806)
----------- -----------
Cash flows from investing activities:
Purchase of property and equipment (113,730) (68,179)
Loans to officers (1,184) (8,581)
Product development loan to affiliate -- (229,761)
Repayment of product development loan to affiliate -- 13,110
----------- -----------
Net cash used in
investing activities (114,914) (293,411)
----------- -----------
Cash flows from financing activities:
Proceeds from stock options exercised 1 141
----------- -----------
Net cash provided by
financing activities 1 141
----------- -----------
Net decrease in cash (1,633,014) (1,572,076)
Cash at beginning of period 3,082,202 8,133,468
----------- -----------
Cash at end of period $ 1,449,188 $ 6,561,392
=========== ===========
</TABLE>
See accompanying notes to condensed consolidated financial statements.
-6-
<PAGE>
NORLAND MEDICAL SYSTEMS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
(1) BASIS OF PRESENTATION
The condensed consolidated financial statements of Norland Medical Systems, Inc.
(the "Company") presented herein, have been prepared pursuant to the rules of
the Securities and Exchange Commission for quarterly reports on Form 10-Q and do
not include all of the information and footnote disclosures required by
generally accepted accounting principles. These statements should be read in
conjunction with the audited financial statements and notes thereto for the year
ended December 31, 1997, and included in the Company's Form 10-K as filed with
the Securities and Exchange Commission on April 9, 1998.
The condensed consolidated financial statements included herein are unaudited
but, in the opinion of management, include all adjustments (consisting of
normal, recurring adjustments) necessary for a fair presentation of the
financial position, results of operations and cash flows for these interim
periods.
The results of operations for the three months ended March 31, 1998 are not
necessarily indicative of the results to be expected for the entire fiscal year
ending December 31, 1998.
(2) INVENTORIES
As of March 31, 1998 and December 31, 1997, inventories consists of the
following:
March 31, 1998 December 31, 1997
-------------- -----------------
Raw materials, product kits,
spare parts and sub-assemblies $ 2,555,818 $2,201,268
Work in progress 266,429 191,069
Rental systems, net 12,943 32,251
Finished goods 4,643,425 4,014,094
Inventory reserve (1,600,000) (1,275,000)
----------- ----------
$ 5,878,615 $5,163,682
=========== ==========
Inventories are stated at the lower of cost or market; cost is determined
principally by the first-in, first-out method.
Systems used in the Company's short-term rental program are carried in inventory
at lower of cost or net realizable value until the time of sale.
-7-
<PAGE>
Norland Medical Systems, Inc.
Notes to Condensed Consolidated Financial Statements (continued):
(unaudited)
(3) NOTE PAYABLE
On September 11, 1997, the Company acquired Norland Corporation ("Norland
Corp.") from Norland Medical Systems B.V. ("NMS BV") in a transaction accounted
for under the purchase method of accounting. The condensed consolidated
financial statements reflect the acquisition of all of the issued and
outstanding stock of Norland Corp. for $17,500,000 from the date of acquisition.
The $17,500,000 consideration consisted of a $1,250,000 cash payment made on
September 11, 1997 and a $16,250,000 Purchase Note (the "Note") bearing interest
at the rate of 7% per annum which is payable quarterly beginning September 30,
1997. A $1,250,000 portion of the Note principal was originally payable in cash
on March 11,1998. The Note has been amended to provide that such payment will
not be due until such time as the Company receives at least $2,000,000 in
proceeds from a debt or equity financing. The remaining principal is due and
payable on September 11, 2002. The Company may prepay the Note at any time, pay
the principal (except for the $1,250,000 payment referred to above) with shares
of Company common stock valued at the time of payment and extend the September
11, 2002 maturity date by up to two years (at increasing rates). NMS BV agreed
that the $284,375 interest payment that was scheduled to be paid March 31, 1998
will not be payable until June 30, 1998. The Note is collateralized by a pledge
of the shares of Norland Corp.
In accordance with APB Opinion No. 21, "Interest on Receivables and Payables,"
the Note has been fair valued as of September 11, 1997 using a market interest
rate of 8.18%, which resulted in the establishment of a $727,539 note discount
that is being amortized using the effective interest method over the Note's
five-year term.
-8-
<PAGE>
Norland Medical Systems, Inc.
Notes to Condensed Consolidated Financial Statements (continued):
(unaudited)
(4) EARNINGS (LOSS) PER SHARE
Effective December 31, 1997, the Company adopted the provisions of SFAS No. 128,
"Earnings per Share." Under SFAS No. 128, basic and diluted earnings per share
replaces primary and fully-diluted earnings per share, respectively. Basic per
share figures are computed using the weighted average number of common shares
outstanding. Diluted per share figures are computed using the weighted average
number of common shares outstanding, after giving effect to dilutive options,
using the treasury stock method. The March 31, 1997 per share figures have been
restated to reflect the provisions of SFAS No. 128.
The calculations of per share results for the quarter ended March 31, 1997 are
as follows:
Numerator:
Income available to common stockholders $ 103,616
Denominator:
Basic weighted average shares outstanding 7,115,831
Effect of dilutive stock options 51,047
Diluted weighted average shares outstanding 7,166,878
Basic earnings per share $ 0.01
Diluted earnings per share 0.01
Options to purchase 731,000 shares of common stock were outstanding at March 31,
1998, but were not included in the computation of diluted loss per share as
their effect would be anti-dilutive.
(5) LITIGATION
A shareholder's class action and derivative complaint, entitled Irwin J. Miller
v. Reynald G. Bonmati et. al. Defendants, and Norland Medical Systems, Inc.,
Nominal Defendant, was filed in the Court of Chancery of the State of Delaware,
New Castle County, on August 1, 1997, against four members of the Company's
Board of Directors, Reynald G. Bonmati, Albert S. Waxman, James J. Baker, and
Michael W. Huber (the "Individual Defendants"), NMS BV, and the Company. The
action relates to the acquisition of Norland Corp. by the Company from NMS BV.
The complaint alleged that the Individual Defendants breached their fiduciary
duties of loyalty, candor, and care in connection with the pending acquisition,
and that the Company's proxy statement relating to the stockholders' meeting to
vote on the acquisition did not contain full and fair disclosure. Plaintiff
sought, among other things: to enjoin the consummation of the acquisition; to
require that the Company make additional disclosures to its stockholders in
connection with the acquisition; damages in unspecified amounts; and costs,
disbursements, and counsel and expert fees. An agreement in principle was
reached to settle this action. The Company delayed its Annual Meeting of
Stockholders and supplemented its proxy statement with respect to the
acquisition and the plaintiff withdrew his application for a preliminary
injunction against the acquisition. It was agreed that the terms of the
$16,250,000, 7% promissory note to be issued as part of the purchase price for
Norland Corp. would be modified to provide that if the Company exercises its
right to elect to extend the maturity date of such note from five years to up to
seven years, the interest rate would be increased by one percentage point at the
end of the fifth year and the sixth year rather than by one percentage point
every six months as originally agreed. The Company also agreed to use its best
efforts to nominate for election to the Board at the 1997 Annual Meeting one
nominee with no direct or indirect affiliation with NMS BV, and, with respect to
each succeeding Annual Meeting, at least two nominees with no direct or indirect
affiliation with NMS BV. Finally, the Company agreed that it would not oppose an
application by plaintiff's counsel for an award of counsel fees and expenses of
up to $250,000. Such amount would be payable by the Company. The acquisition was
approved by the Company's stockholders at the Annual Meeting of Stockholders
held on September 8, 1997, and the acquisition was consummated on September 11,
1997. A definitive Stipulation of Settlement has been executed. Robert L.
Piccioni and Joan Piccioni, plaintiffs in the action referred to below, have
filed an objection to the settlement. A hearing in the Delaware Court of
Chancery to determine whether the Stipulation of Settlement should be approved
is scheduled to be held on June 2, 1998. Included within accrued expenses at
March 31, 1998 is $250,000 related to the settlement of this action. There can
be no assurances that the Stipulation
-9-
<PAGE>
Norland Medical Systems, Inc.
Notes to Condensed Consolidated Financial Statements (continued):
(unaudited)
of Settlement will be approved by the Court, or that, if not approved, the
Company's liability will be limited to $250,000.
The Company and Norland Corp. were named as defendants in an action, entitled
Robert L. Piccioni, Ph.d. and Joan Piccioni v. Norland Medical Systems, et al.,
brought by Robert L. Piccioni, a former director of the Company, and Joan
Piccioni, the former President of the Company's subsidiary, Dove Medical
Systems, Inc. ("Dove"), in the United States District Court for the Central
District of California. The action was commenced shortly after the Company made
claims for indemnification from Dr. and Mrs. Piccioni and certain other former
stockholders of Dove in connection with the Company's acquisition of Dove in
April of 1996. The complaint was subsequently amended to add Reynald G. Bonmati,
the Company's President and Chairman of the Board, and Albert S. Waxman, a
director of the Company, as defendants. The Piccionis allege breach of contract
and fraud by the Company in connection with the acquisition of Dove, claim they
suffered damages in excess of $2,500,000, and seek the release of the portion of
the purchase price paid for Dove that is held in escrow to be available to
satisfy indemnity obligation of the Piccionis and such other former stockholders
of Dove to the Company. The defendants have moved to dismiss certain of the
Piccionis' claims. These motions are pending before the Court. The Company
believes that the Piccionis' action is without merit.
On April 12, 1998 a complaint entitled Wesley D. Johnson and Pamela S. T.
Johnson v. Reynald G. Bonmati, Kurt W. Streams, and Norland Medical Systems,
Inc., was filed in the United States District Court for the Southern District of
New York against the Company, Reynald G. Bonmati, its Chief Executive Officer,
and Kurt W. Streams, its Chief Financial Officer. The complaint makes claims
under Sections 10(b) and 20 of the Securities Exchange Act of 1934, arising from
the Company's announcement on March 16, 1998 that it would be restating its
financial statements with respect to the fourth quarter of 1996, and the first,
second, and third quarters of 1997. The claims are made on behalf of a purported
class of certain persons who purchased the Company's Common Stock from February
25, 1997 through March 16, 1998. Plaintiffs seek compensatory damages in an
unspecified amount, together with prejudgement interest, costs and expenses
(including attorneys' fees and disbursements). The defendants' time to respond
to the complaint has not yet expired.
In addition, in the normal course of business, the Company is named in lawsuits
in which claims are asserted against the Company. In the opinion of management,
the liabilities, if any, which may ultimately result from such lawsuits are not
expected to have a material adverse effect on the financial position, results of
operations, or cash flows of the Company.
(6) RESTATEMENT OF FINANCIAL INFORMATION
The Company has restated its financial statements for the quarter ended March
31, 1997. A review of sales transactions recorded in the quarter revealed that
certain transactions that the Company treated as sales, and with respect to
which it recognized revenue, should not have been treated as sales for purposes
of revenue recognition. As a result, the March 31, 1997 financial statements
were restated to eliminate the transactions that should not have been treated as
sales.
-10-
<PAGE>
Norland Medical Systems, Inc.
Notes to Condensed Consolidated Financial Statements (continued):
(unaudited)
All material adjustments necessary to correct the financial statements have been
recorded. The impact of these adjustments on the Company's March 31, 1997
financial results as originally reported is summarized as follows:
As Reported As Restated
----------- -----------
Net revenue $ 5,946,285 $ 4,337,203
Gross profit 3,384,872 1,854,329
Operating income 660,204 37,722
Net income 473,098 103,616
Earnings per share - diluted 0.07 0.01
Total assets 30,266,158 29,646,105
Total current liabilities 3,272,054 3,435,002
Retained earnings 4,832,341 4,049,340
(7) FUTURE IMPACT OF RECENT ACCOUNTING PRONOUNCEMENTS
SFAS No. 130, "Reporting Comprehensive Income," requires that comprehensive
income and its components be reported in the financial statements. Comprehensive
income represents the change in net assets of a business enterprise as a result
of nonowner transactions. The Company adopted this standard during the first
quarter of 1998 with no impact on the financial statements as there were no
other comprehensive income components.
SFAS No. 131, "Disclosures About Segments of an Enterprise and Related
Information," requires that publicly traded companies report financial and
descriptive information about its reportable operating segments. The Company is
required to adopt this standard in the fourth quarter of 1998 and is currently
evaluating the impact of this standard.
-11-
<PAGE>
Norland Medical Systems, Inc.
Item 2. Management's Discussion and Analysis of Financial Condition and Results
of Operations
The following discussion of the financial condition and results of operations of
the Company should be read in conjunction with the Financial Statements and the
related Notes thereto included elsewhere in this Report.
RESULTS OF OPERATIONS
Revenue for the three months ended March 31, 1998 decreased $2,274,496 (52.4%)
to $2,062,707 from $4,337,203 for the comparable period of 1997. The decrease in
sales was largely a result of significantly decreased sales of its DXA-based
systems in the United States and Pacific Rim. The Company believes that sales in
the United States have been adversely affected by uncertainties and confusion in
the primary care physician market over various factors, including applicable
Medicare reimbursement rates. Sales in the United States and Pacific Rim
represented 60.8% and 13.1%, respectively, of total revenue for the three months
ended March 31, 1998 and 71.2% and 15.3%, respectively, of total revenue for the
three months ended March 31, 1997. A majority of the Company's revenues for the
three-month periods ended March 31, 1998 and 1997 was derived from sales of the
Eclipse and XR36 central systems. Sales of complete bone densitometry systems
represented 86.1% and 89.8% of total revenue for the three months ended March
31, 1998 and 1997, respectively. Sales of parts and services and rental income
comprised the balance of revenues for such periods.
Sales in the United States have been affected by changes in the Medicare
reimbursement rates for bone densitometry tests. In November 1996 the Health
Care Financing Administration (HCFA) announced changes for 1997 that
significantly reduced the reimbursement rate for peripheral bone densitometry
tests. In June 1997 HCFA published proposed changes for 1998 that would have
increased the reimbursement rate for peripheral systems and significantly
reduced the rate for central systems. These proposed reimbursement rates for
1998 were not adopted by HCFA. Instead, the 1998 rates for both peripheral and
central systems, as finally adopted, were increased slightly over their
applicable rates for 1997. Such reimbursement rates are subject to further
changes. Currently, several regional Medicare carriers do not allow any
reimbursement for peripheral bone densitometry tests. However, effective July 1,
1998, HCFA national policy will provide for Medicare coverage of bone density
diagnostic tests for the purpose of identifying bone mass or detecting bone loss
for qualified individuals. Revenues and the mix of products sold are expected to
continue to be influenced by the relative degree of difference in reimbursement
rate levels for peripheral and central systems. They will also be influenced by
the Company's ability to bring to the market systems that can be operated more
profitably by end users at the applicable reimbursement levels.
Cost of revenue as a percentage of revenue was 87.6% and 57.2% for the three
months ended March 31, 1998 and 1997, respectively, resulting in a gross margin
of 12.4% for the three months ended March 31, 1998 compared to 42.8% for the
comparable period of 1997. The gross margin for the first quarter of 1998 was
adversely affected by a $325,000 charge for an increased inventory reserve. In
addition, because Norland Corp. has certain fixed manufacturing costs each
quarter, to the extent that revenues are lower, such fixed costs have a more
negative impact on gross margins.
-12-
<PAGE>
Norland Medical Systems, Inc.
Results of Operations (continued):
Sales and marketing expense increased $562,435 (51.0%) to $1,664,575 for the
three months ended March 31, 1998 from $1,102,140 for the three months ended
March 31, 1997, and increased as a percentage of revenue to 80.7% from 25.4%.
The dollar increase was primarily due to expenses of sales and marketing
personnel hired during 1997, the continuing cost of marketing efforts that were
expanded during 1997, and increased expenses of the Company's customer service
department required to support the expanding installed base of systems in the
United States.
General and administrative expense increased $436,629 (72.6%) to $1,037,809 for
the three months ended March 31, 1998 from $601,180 for the three months ended
March 31, 1997 and increased as a percentage of revenue to 50.3% from 13.9%. The
largest component of the increase was the inclusion of $245,000 in general and
administrative expenses of Norland Corp., including $149,000 of goodwill
amortization expense related to the Company's acquisition of Norland Corp. on
September 11, 1997. Other factors contributing to the increase were bad debt
expenses and increased expenses of personnel and professional fees. The
increases were partially offset by the elimination of expenses for the Company's
Dove Medical Systems subsidiary, which ceased operations in September 1997.
Research and development expense increased $306,555 (270.6%) to $419,842 for the
three months ended March 31, 1998 from $113,287 for the three months ended March
31, 1997, and also increased as a percentage of revenue to 20.4% from 2.6%. The
dollar increase was primarily the result of the inclusion of research and
development expenses of Norland Corp., and was partially offset by the
elimination of expenses of Dove Medical Systems.
The increases in expense as a percentage of revenues for the quarter ended March
31, 1998 referred to in the three preceding paragraphs are also attributable to
the Company's reduced revenues in the quarter.
Interest expense of $318,018 for the three months ended March 31, 1998
represents interest on the Purchase Note issued by the Company in connection
with the acquisition of Norland Corporation on September 11, 1997. Interest
income in the three-month periods ended March 31, 1998 and 1997 consisted
primarily of interest earned on the Company's cash and loan balances, reduced by
other expenses consisting primarily of bank charges and other fees related to
bank transfers. The decrease in interest income in the three-month period ended
March 31, 1998 as compared to March 31, 1997 reflects reduced interest income
resulting from the Company's reduced cash position.
The income tax benefit as a percentage of loss before income taxes was 39.8% for
the quarter ended March 31, 1998, as compared to a provision for income taxes of
40.7% for the same period in 1997. Management believes that based on the
Company's history of operating earnings, exclusive of the nonrecurring charges
in 1997, and its expected income, it is more likely than not that future levels
of income will be sufficient to realize the deferred tax assets, as recorded.
The Company had a net loss of $1,889,582 ($0.26 per share) for the three months
ended March 31, 1998 compared to net income of $103,616 ($0.01 per share) for
the three months ended March 31, 1997. The change was due primarily to the
factors discussed above.
-13-
<PAGE>
Norland Medical Systems, Inc.
Results of Operations (continued):
LIQUIDITY AND CAPITAL RESOURCES
At December 31, 1997, the Company had cash of $3,082,202. At March 31, 1998, the
Company had cash of $1,449,188. The decrease in cash was primarily the result of
the payment of operating expenses, increased inventories, and decreased
accounts payable.
The Company's accounts receivable decreased $1,937,789 (31.4%) to $4,227,678 at
March 31, 1998 from $6,165,467 at December 31, 1997, reflecting the lower
revenues for the quarter. At March 31, 1998, the two largest balances, 26.4% and
14.5% of total outstanding trade receivables, were owed by two U.S.
distributors.
Property and equipment as of March 31, 1998 consisted of leasehold improvements,
computer and telephone equipment, a management information system, office
furniture, and tooling for the products manufactured by the Company. At the
present time, except for additional tooling, no significant expenditures for
additional equipment of systems are planned for 1998.
The Purchase Note issued to NMS BV as part of the purchase price for Norland
Corp. has been amended to provide that the $1,250,000 principal payment
originally due on March 11, 1998 will not be payable until such time as the
Company receives at least $2,000,000 from a debt or equity financing. Depending
on when such principal payment is made, interest payments on the Purchase Note
will range from approximately $285,000 to $265,000 per quarter. NMS BV has
agreed that the $284,375 interest payment that was scheduled to be paid on March
31, 1998 will not be payable until June 30, 1998.
The Company plans to fund its ongoing operations from its cash position and cash
flow from operations (including tax refunds). In order to increase its cash
flow, the Company is seeking to stimulate sales and reduce its inventory levels.
Since the Company has already paid suppliers for most of its inventory, the bulk
of the proceeds from the sale of such inventory will be retained by the Company,
thereby increasing liquidity. The Company will be required to use working
capital to build up inventory of its recently introduced Apollo DXA system that
measures bone density at the heel. The Company is also continuing to focus its
efforts on improving the aging of its accounts receivable. To do so, the Company
is implementing higher credit standards for its customers and is emphasizing the
receipt of down payments from customers at the time their purchase orders are
received. The Company is also continuing to be more aggressive in seeking to
collect outstanding receivables.
The Company has been advised by The Nasdaq Stock Market ("Nasdaq") that the
Company is not in compliance with the requirement that listed companies maintain
net tangible assets of at least $4 million. The Company has requested a hearing
to appeal Nasdaq's plan to delist the Company's Common Stock from the National
Market System as a result of such noncompliance. The date for the hearing has
not yet been set. The Company is currently exploring various plans to achieve
full compliance with the listing requirements. There can be no assurance as to
the success of any such plan.
-14-
<PAGE>
Norland Medical Systems, Inc.
Results of Operations (continued):
The Company is seeking equity financing to increase its working capital and net
tangible assets. The Company does not have a commitment for such financing, and
there can be no guarantee that the Company will be able to obtain such
financing. The failure to do so could materially adversely affect the Company
and its operations. In addition, the nature of the Company's business is such
that it is subject to changes in technology, government approval and regulation,
and changes in third-party reimbursement in the United States and numerous
foreign markets. Significant changes in one or more of these factors in a major
market for the Company's products could significantly affect the Company's cash
needs.
-15-
<PAGE>
Norland Medical Systems, Inc.
PART II OTHER INFORMATION
Item 1. Legal Proceedings
A shareholder's class action and derivative complaint, entitled Irwin I.
Miller v. Reynald G. Bonmati et al., Defendants, and Norland Medical
Systems, Inc., Nominal Defendant, was filed in the Court of Chancery of
the State of Delaware, New Castle County, on August 1, 1997, against
four members of the Company's Board of Directors, Reynald G. Bonmati,
Albert S. Waxman, James J. Baker, and Michael W. Huber (the "Individual
Defendants"), NMS BV, and the Company. The action relates to the
acquisition of Norland Corp. by the Company from the NMS BV. The
complaint alleged that the Individual Defendants breached their
fiduciary duties of loyalty, candor, and care in connection with the
pending acquisition, and that the Company's proxy statement relating to
the stockholders' meeting to vote on the acquisition did not contain
full and fair disclosure. Plaintiff sought, among other things: to
enjoin the consummation of the acquisition; to require that the Company
make additional disclosures to its stockholders in connection with the
acquisition; damages in unspecified amounts; and costs, disbursements,
and counsel and expert fees. An agreement in principle was reached to
settle this action. The Company delayed its Annual Meeting of
Stockholders and supplemented its proxy statement with respect to the
acquisition and the plaintiff withdrew his application for a preliminary
injunction against the acquisition. It was agreed that the terms of the
$16,250,000, 7% promissory note to be issued as part of the purchase
price for Norland Corp. would be modified to provide that if the Company
exercises its right to elect to extend the maturity date of such note
from five years to up to seven years, the interest rate would be
increased by one percentage point at the end of the fifth year and the
sixth year rather than by one percentage point every six months as
originally agreed. The Company also agreed to use its best efforts to
nominate for election to the Board at the 1997 Annual Meeting one
nominee with no direct or indirect affiliation with NMS BV, and, with
respect to each succeeding Annual Meeting, at least two nominees with no
direct or indirect affiliation with NMS BV. Finally, the Company agreed
that it would not oppose an application by plaintiff's counsel for an
award of counsel fees and expenses of up to $250,000. Such amount would
be payable by the Company. The acquisition was approved by the Company's
stockholders at the Annual Meeting of Stockholders held on September 8,
1997, and the acquisition was consummated on September 11, 1997. A
definitive Stipulation of Settlement has been executed. Robert L.
Piccioni and Joan Piccioni, plaintiffs in the action referred to below,
have filed an objection to the settlement. A hearing in the Delaware
Court of Chancery to determine whether the Stipulation of Settlement
should be approved is scheduled to be held on June 2, 1998. There can be
no assurances that the Stipulation of Settlement will be approved by the
Court, or that, if not approved, the Company's liability will be limited
to $250,000.
-16-
<PAGE>
Norland Medical Systems, Inc.
Item 1. Legal Proceedings (continued)
The Company and Norland Corp. were named as defendants in an action,
entitled Robert L. Piccioni, Ph.D. and Joan Piccioni v. Norland Medical
Systems, Inc. and Norland Corp., brought by Robert L. Piccioni, a former
director of the Company, and Joan Piccioni, the former President of the
Company's Dove subsidiary, in the United States District Court for the
Central District of California. The action was commenced shortly after
the Company made claims for indemnification from Dr. and Mrs. Piccioni
and certain other former stockholders of Dove in connection with the
Company's acquisition of Dove in April of 1996. The complaint was
subsequently amended to add Reynald G. Bonmati, the Company's President
and Chairman of the Board, and Albert S. Waxman, a director of the
Company, as defendants. The Piccionis allege breach of contract and
fraud by the Company in connection with the acquisition of Dove, claim
they suffered damages in excess of $2,500,000, and seek the release of
the portion of the purchase price paid for Dove that is held in escrow
to be available to satisfy indemnity obligation of the Piccionis and
such other former stockholders of Dove to the Company. The defendants
have moved to dismiss certain of the Piccionis' claims. These motions
are pending before the Court. The Company believes that the Piccionis'
action is without merit.
On April 12, 1998 a complaint entitled Wesley D. Johnson and Pamela S.
T. Johnson v. Reynald G. Bonmati, Kurt W. Streams, and Norland Medical
Systems, Inc., was filed in the United States District Court for the
Southern District of New York against the Company, Reynald G. Bonmati,
its Chief Executive Officer, and Kurt W. Streams, its Chief Financial
Officer. The complaint makes claims under Sections 10(b) and 20 of the
Securities Exchange Act of 1934, arising from the Company's announcement
on March 16, 1998 that it would be restating its financial statements
with respect to the fourth quarter of 1996, and the first, second, and
third quarters of 1997. The claims are made on behalf of a purported
class of certain persons who purchased the Company's Common Stock from
February 25, 1997 through March 16, 1998. Plaintiffs seek compensatory
damages in an unspecified amount, together with prejudgement interest,
costs and expenses (including attorneys' fees and disbursements). The
defendants' time to respond to the complaint has not yet expired.
Item 2. Change in Securities
None
Item 3. Defaults Upon Senior Securities
None
-17-
<PAGE>
Norland Medical Systems, Inc.
Item 4. Submission of Matters to a Vote of Security Holders
None
Item 5. Other Information
The Company has been advised by The Nasdaq Stock Market ("Nasdaq") that
the Company is not in compliance with the requirement that listed
companies maintain net tangible assets of at least $4 million. The
Company has requested a hearing to appeal Nasdaq's plan to delist the
Company's Common Stock from the National Market System as a result of
such noncompliance. The date for the hearing has not yet been set. The
Company is currently exploring various plans to achieve full compliance
with the listing requirements. There can be no assurance as to the
success of any such plan.
Item 6. Exhibits and Reports on Form 8-K
(a) Exhibits furnished:
27 Financial Data Schedule
(b) Reports on Form 8-K:
The Company filed a Report on Form 8-K on March 17, 1998 reporting
the Company's decision to restate its financial statements with
respect to the fourth quarter of 1996 and the first, second, and
third quarters of 1997.
-18-
<PAGE>
Norland Medical Systems, Inc.
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
NORLAND MEDICAL SYSTEMS, INC.
--------------------------------------------
(Registrant)
Date: May 15, 1998 /s/ Reynald G. Bonmati
--------------------------------------------
Reynald G. Bonmati
President
Date: May 15, 1998 /s/ Kurt W. Streams
--------------------------------------------
Kurt W. Streams
Vice President, Finance
(Principal Financial and Accounting Officer)
-19-
<PAGE>
Norland Medical Systems, Inc.
Exhibit Index
Number Description
- ------ -----------
27 Financial Data Schedule
-20-
<TABLE> <S> <C>
<ARTICLE> 5
<LEGEND>
This schedule contains summary financial information extracted from the
Condensed Financial Statements and is qualified in its entirety by reference to
such financial statements.
</LEGEND>
<S> <C>
<PERIOD-TYPE> 3-MOS
<FISCAL-YEAR-END> Dec-31-1998
<PERIOD-END> Mar-31-1998
<CASH> 1,449,188
<SECURITIES> 0
<RECEIVABLES> 6,427,678
<ALLOWANCES> 2,200,000
<INVENTORY> 5,938,409
<CURRENT-ASSETS> 15,387,966
<PP&E> 2,433,791
<DEPRECIATION> 1,580,343
<TOTAL-ASSETS> 26,745,203
<CURRENT-LIABILITIES> 6,539,706
<BONDS> 14,484,093
0
0
<COMMON> 3,581
<OTHER-SE> 5,717,823
<TOTAL-LIABILITY-AND-EQUITY> 26,745,203
<SALES> 2,004,465
<TOTAL-REVENUES> 2,062,707
<CGS> 1,805,914
<TOTAL-COSTS> 1,805,914
<OTHER-EXPENSES> 3,122,226
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 318,018
<INCOME-PRETAX> (3,139,582)
<INCOME-TAX> (1,250,000)
<INCOME-CONTINUING> (1,889,582)
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (1,889,582)
<EPS-PRIMARY> (0.26)
<EPS-DILUTED> (0.26)
</TABLE>
